Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Faenza – page 27

1 309 clinical trials in Faenza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Faenza at a glance
1 309
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 309 trials in Faenza

Open in trial search

Study of Azacitidine, Venetoclax, and Tagraxofusp for Patients with Higher-Risk Chronic Myelomonocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:GCP-Service International West GmbH

Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Ascentage Pharma Group Inc.

Study on Losartan and Hydrochlorothiazide for Osteogenesis Imperfecta in Patients Aged 16 and Above

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrochlorothiazide
  • Sponsor:Istituto Ortopedico Rizzoli

Study Comparing Gemcitabine and Paclitaxel with Drug Combination for Patients with Advanced Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Study of Olaparib for Patients with Recurrent Ovarian Cancer Without BRCA Gene Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Fondazione Ricerca Traslazionale

Study of gemtuzumab ozogamicin with chemotherapy for adults aged 18-60 with newly diagnosed favorable-intermediate-risk acute myeloid leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Study on Acoramidis for Preventing Transthyretin Amyloidosis in Young People with a Genetic Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:Eidos Therapeutics Inc.

Myelofibrosis

Recruiting

Study on the Safety of Roginolisib and Ruxolitinib for Patients with Myelofibrosis Unresponsive to JAK Inhibitors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fedratinib
  • Sponsor:iOnctura SA

Study Comparing Metformin and Tolvaptan for Adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Metformin
  • Sponsor:University Of Bari Aldo Moro

Study on Atezolizumab for Patients with Malignant Pleural Mesothelioma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Study to Optimize Cytokine Release Syndrome for Glofitamab with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Faenza

What the registry says about research in the country

01 Oncology Research - Lung Cancer

Innovative clinical trials focusing on non-small cell lung cancer and small-cell lung cancer, evaluating novel combination therapies and targeted treatments.

  • Advanced NSCLC treatment studies
  • KRAS G12C mutation therapies
  • Immunotherapy combinations

Multiple studies examining maintenance therapies and first-line treatment options for lung cancer patients.

02 Gynecologic Oncology

Comprehensive research in ovarian cancer, including studies on maintenance therapies and novel treatment approaches for recurrent disease.

  • BRCA-related treatments
  • Advanced peritoneal cancer
  • Endometrial cancer therapies

Investigations into new therapeutic combinations and targeted treatments for gynecologic malignancies.

03 Gastrointestinal Cancer Research

Studies examining treatments for various gastrointestinal cancers, including innovative approaches for colorectal and gastric cancers.

  • Microsatellite instability studies
  • Biliary tract cancer treatments
  • Immunotherapy applications

Focus on personalized treatment approaches and combination therapies for GI tract malignancies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.